Urteste S.A. (WSE:URT)

Poland flag Poland · Delayed Price · Currency is PLN
49.80
-0.60 (-1.19%)
Mar 6, 2026, 10:47 AM CET
-45.03%
Market Cap 71.05M
Revenue (ttm) 1.80M
Net Income (ttm) -5.47M
Shares Out 1.41M
EPS (ttm) -3.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 255
Average Volume 379
Open 50.20
Previous Close 50.40
Day's Range 49.80 - 50.20
52-Week Range 24.00 - 91.00
Beta 0.08
RSI 44.54
Earnings Date Apr 29, 2026

About Urteste

Urteste S.A. engages in the research and development of diagnostic tests for cancers. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, bile ducts, stomach, lung, esophagus, ovary, endometrium, blood, breast, and brain. The company was incorporated in 2021 and is based in Gdańsk, Poland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Employees 36
Stock Exchange Warsaw Stock Exchange
Ticker Symbol URT
Full Company Profile

Financial Performance

In 2024, Urteste's revenue was 1.80 million, an increase of 35.34% compared to the previous year's 1.33 million. Losses were -3.63 million, -35.00% less than in 2023.

Financial Statements

News

There is no news available yet.